Roginolisib with Venetoclax and Rituximab for Relapsed/Refractory CLL
This study is testing a combination of three drugs, Roginolisib, Venetoclax, and Rituximab, for people with chronic lymphocytic leukemia (CLL) that has come back or not responded to previous treatments. Roginolisib is a new drug being studied, while Venetoclax and Rituximab are already approved for CLL. Researchers want to see if adding Roginolisib leads to better results than Venetoclax and Rituximab alone. You might be able to join if you have relapsed or refractory CLL and meet specific criteria, such as having a certain number of B cells in your blood or enlarged lymph nodes. The main goal is to see how many people achieve undetectable minimal residual disease (uMRD) after one year, meaning very few cancer cells remain.
- Study design
- This is a Phase I/II, open-label, randomized study with 64 planned participants. You would be randomly assigned to receive either Roginolisib plus Venetoclax and Rituximab, or Venetoclax and Rituximab alone.
- What's involved
- Study procedures include in-clinic visits, blood tests, urine tests, ECGs (heart tests), CT scans, MRI scans, and bone marrow biopsies/aspirations.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary endpoint is measured at 1 year.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
NCT06644183
Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)
Recruiting
PHASE1Ages 18+InterventionalTreatmentJennifer R. Brown, MD, PhDInvestigator-initiated
~64 participants
Updated 2026-02-11 on ClinicalTrials.gov
What's tested:RoginolisibVenetoclaxRituximab
At a glance
Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Undetectable Minimal Residual Disease(uMRD) rate by ClonoSEQ assay
Measured over 1 year
Conditions
NCT06644183
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Dana-Farber Cancer Institute
Boston, Massachusettsstudy coordinator listed
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Jennifer Brown, MD, PhD · PRINCIPAL_INVESTIGATOR · Dana-Farber Cancer Institute
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Want this trial checked against your situation?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Patients with relapsed/refractory CLL who meet iwCLL criteria for requiring treatment.
Patients with measurable disease as defined by at least one of: circulating lymphocytosis \> 5000 B cells/microliter, bone marrow involvement \> 30%, palpable splenomegaly or lymph nodes \> 1.5 cm. Computer tomography (CT) at screening must be performed and followed every 2 cycles (1 cycle = 28 days).
Patients must have received at least two prior therapies for CLL including systemic therapy containing a covalent BTK inhibitor.
Patients willing to undergo a pre-treatment and on treatment bone marrow biopsy.
Age ≥18 years, at the time of signing the IRB approved informed consent. Because no dosing or adverse event data are currently available on the use of venetoclax in combination with roginolisib in participants \<18 years of age, children are excluded from this study, but will be eligible for future pediatric trials.
Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2.
Participants must meet the following organ and marrow function as defined below:
Platelet count ≥50 x 109/L\^\^\^
Total bilirubin ≤ 1.5 ×institutional upper limit of normal (ULN)\*
AST(SGOT)/ALT(SGPT) ≤3.0 × institutional ULN
Creatinine clearance ≥ 60 mL/min\*\*
\^\^\^Thrombocytopenia due to marrow involvement of CLL: \> 30 x 109/L for the safety run-in, and 20 x 109/L for the randomized portion of the study
\*unless increase attributed to leukemic organ involvement, hemolysis or Gilbert's syndrome. Patients who are \< 75 years may have bilirubin of ≤ 3.0 × ULN
\*\* calculated by the Cockcroft Gault formula or measured by 24 hours urine collection
Patients with clinically inactive CNS disease or treated CNS disease that is no longer symptomatic, or who need corticosteroids or anticonvulsants may be enrolled in the study. For patients who have symptoms present, imaging and lumbar puncture must be performed to exclude a CNS condition that may impact the study conduct.
Willingness to undergo a pre-treatment and on-treatment bone marrow to evaluate MRD.
Willingness to use adequate contraception prior to study entry and for the duration of study participation.
The effects of roginolisib on the developing human fetus are unknown.
Venetoclax may cause embryo fetal harm when administered to pregnant women. Anti-CD20 targeting agents are likely to cause fetal B-cell depletion. For this reason women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Women of child-bearing potential will be required to have a negative serum pregnancy test during screening and a negative serum pregnancy test on Cycle 1 Day 1. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.
Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of roginolisib or venetoclax administration. Contraception must be conducted up to 12 months after taking the last rituximab dose.
Ability to understand and the willingness to sign a written informed consent document, which includes compliance with the requirements of this protocol.
Eligible to receive infection prophylaxis and supportive care as per institutional guidelines.
Known Human immunodeficiency virus (HIV) infection which is treated with agents that can interfere with venetoclax due to potential drug-drug interactions or increased risk of myelotoxicity.
Any serious or uncontrolled medical disorder or active infection that, in the opinion of the Investigator, may increase the risk associated with study participation, study drug administration, or would impair the ability of the patient to receive protocol therapy.
Known alcohol or substance abuse.
Exclusion
Patients who have received prior treatment with venetoclax or PI3K inhibitors in the last 6 months. Patients must not have had any CLL-directed anticancer therapy within 5 half- lives of the therapy prior to Cycle 1 Day 1.
Patients who have received a live vaccine within 30 days of planned start of study therapy. With regards to other type of vaccines, including SARS-Co2 vaccines, these are allowed.
Patients requiring ongoing treatment with chronic high dose immunosuppressants (e.g., cyclosporine) or systemic steroids \> 20 mg prednisone (or equivalent) QD. For example, patients with uncontrolled autoimmune haemolytic anaemia (AIHA) or idiopathic thrombocytopenia purpura (ITP), which requires \> 20 mg once daily (QD) of prednisone (or equivalent) to maintain haemoglobin levels of \>8.0 g/dL or platelets \> 10,000 mL without transfusion support.
History of transformation of CLL to aggressive non-Hodgkin lymphoma (Richter´s transformation or pro-lymphocytic leukaemia) which may otherwise interfere with the interpretation of the outcome of the study (including biomarker evaluation).
Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities \> Grade 1) with the exception of alopecia or fatigue. Any irAEs from prior immunotherapy must have complete resolution and must have resolved at least 2 weeks before Cycle1 Day1.
Participants who are receiving any other investigational agents for this condition.
History of allergic reactions attributed to compounds of similar chemical or biologic composition to roginolisib or venetoclax or their formulation components or prior anti- CD20 targeting agents more than 6 months before initiating study treatments.
Patients with a history of systemic autoimmune disease.
Participants receiving any medications or substances that are strong inhibitors or inducers of CYP3A are ineligible. Moderate CYP3A inhibitors and P-gp inhibitors can be administered when venetoclax dose is reduced to 50%. Otherwise, venetoclax is contraindicated in patients requiring strong or moderate CYP3A inducers.
Because of ongoing research, regularly consulting medical reference databases is recommended. One such reference is the Website of the US-FDA: (Drug Interactions \| Relevant Regulatory Guidance and Policy Documents \| FDA)
As part of the enrollment/informed consent procedures, the participant will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the participant is considering a new over-the-counter medicine or herbal product.
Pregnant women are excluded from this study because venetoclax has the potential to cause embryo-fetal harm, and the potential for teratogenic or abortifacient effects with roginolisib is currently unknown. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with roginolisib or venetoclax breastfeeding should be discontinued if the mother is treated with these agents.
Patients with a history of other primary malignancy are excluded when they require therapy that will interfere with the investigational treatments. Exceptions are if the natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen. For example:
Malignancies surgically treated with curative intent and with no known active disease present for ≥2 years before the first dose of study treatment.
Adequately treated nonmelanoma skin cancer or lentigo maligna without evidence of disease.
Adequately treated cervical carcinoma in situ without evidence of disease.
Surgically/adequately treated low-grade, early-stage, localized prostate cancer without evidence of disease or low risk localized prostate cancer on observation.
Inability to swallow food or any condition of the upper gastrointestinal tract that precludes administration of oral medications.
History or presence of cardiovascular disease, which in the Investigator's opinion may impact the clinical trial participation. Patients with a QTcF \> 470 msec at screening.
History of tuberculosis treatment within the preceding two years.
What this trial measures
- Undetectable Minimal Residual Disease(uMRD) rate by ClonoSEQ assay1 year
uMRD rate is defined as the proportion of participants with uMRD after treatment with either roginolisib plus venetoclax + rituximab, or venetoclax+ rituximab, as measured in bone marrow at a level of 10-4 by the clonoSEQ assay.